

WHAT IS CLAIMED IS:

- 1                   1.     A method of treating a subject having a pathologic condition  
2 involving neovascularization comprising administering a pharmaceutical preparation  
3 comprising an R'-Glu-Trp-R" dipeptide and a pharmaceutically acceptable carrier to the  
4 subject in an amount effective to inhibit neovascularization.
- 1                   2.     The method of claim 1 wherein the R'-Glu-Trp-R" dipeptide is L-  
2 Glu-L-Trp.
- 1                   3.     The method of claim 2 wherein the condition is hemangioma.
- 1                   4.     The method of claim 2 wherein the condition is vascularized  
2 malignant tumor or vascularized benign tumor.
- 1                   5.     The method of claim 2 wherein the condition is neovascularization  
2 in post-recovery cerebrovascular accident; neovascularization due to head trauma;  
3 restenosis following angioplasty; or neovascularization due to heat or cold trauma.
- 1                   6.     The method of claim 2 wherein the condition is neovascularization  
2 associated with substance-induced neovascularization of the liver, angiogenic  
3 dysfunction related to an excess of hormone; neovascular sequelae of diabetes;  
4 neovascular sequelae to hypertension; or chronic liver infection.
- 1                   7.     The method of claim 2 comprising administering to the subject a  
2 dose of about 0.5  $\mu$ g per 1 kilogram body weight to about 1 mg per 1 kg body weight.
- 1                   8.     The method of claim 7 wherein the effective amount is about  
2 1  $\mu$ g/kg to about 50  $\mu$ g/kg body weight.
- 1                   9.     The method of claim 7 wherein the dose is administered daily  
2 over a period of 1 day to about 30 days.

1 10. The method of claim 7 wherein the pharmaceutical preparation is  
2 administered intramuscularly or intranasally.

1 11. The method of claim 2 comprising administering the  
2 pharmaceutical preparation in the form of an injectable solution containing 0.001% to  
3 0.01% of L-Glu-L-Trp.

1 12. The method of claim 2 comprising administering the preparation  
2 in a unit dose form comprising a tablet, a suppository, a capsule, an eye film, an  
3 inhalant, a mucosal spray, a nose drop, an eye drop, a toothpaste, an ointment, or water  
4 soluble based cream.

1 13. The method of claim 12 wherein said unit dose form consists  
2 essentially of 0.01 mg of said R'-Glu-Trp-R".

1 14. The method of claim 2 further comprising administering to the  
2 subject a vasoactive drug.

1 15. The method of claim 14 wherein the vasoactive drug is an  
2 angiotensin converting enzyme (ACE) inhibitor or a potassium channel opener (PCO).

1 16. The method of claim 2 wherein the subject suffers from a tumor  
2 wherein the method further comprises administering a chemotherapeutic agent.

1 17. The method of claim 2 wherein the subject is not immune  
2 compromised.

add  
4B1  
F3